In contrast to 4T1 tumor cells, which did not markedly express B7-1 and PD-L1, CT26 tumor cells expressed a low level of PD-L1 but a high level of B7-1 (see Results); hence their practicability for immune checkpoint combination therapy, specifically with anti-CTLA-4. This evidence concerns the gene CTLA4 and neoplasm.